TY - JOUR
T1 - Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity
T2 - A conceptual investigation
AU - Saad-Roy, Chadi M.
AU - Levin, Simon A.
AU - Metcalf, C. Jessica E.
AU - Grenfell, Bryan T.
N1 - Publisher Copyright:
© 2021 The Authors.
PY - 2021/2
Y1 - 2021/2
N2 - SARS-CoV-2 is an international public health emergency; high transmissibility and morbidity and mortality can result in the virus overwhelming health systems. Combinations of social distancing, and test, trace, and isolate strategies can reduce the number of new infections per infected individual below 1, thus driving declines in case numbers, but may be both challenging and costly. These interventions must also be maintained until development and (now likely) mass deployment of a vaccine (or therapeutics), since otherwise, many susceptible individuals are still at risk of infection. We use a simple analytical model to explore how low levels of infection, combined with vaccination, determine the trajectory to community immunity. Understanding the repercussions of the biological characteristics of the viral life cycle in this scenario is of considerable importance. We provide a simple description of this process by modelling the scenario where the effective reproduction number Reff is maintained at 1. Since the additional complexity imposed by the strength and duration of transmission-blocking immunity is not yet clear, we use our framework to probe the impact of these uncertainties. Through intuitive analytical relations, we explore how the necessary magnitude of vaccination rates and mitigation efforts depends crucially on the durations of natural and vaccinal immunity. We also show that our framework can encompass seasonality or preexisting immunity due to epidemic dynamics prior to strong mitigation measures. Taken together, our simple conceptual model illustrates the importance of individual and vaccinal immunity for community immunity, and that the quantification of individuals immunized against SARS-CoV-2 is paramount.
AB - SARS-CoV-2 is an international public health emergency; high transmissibility and morbidity and mortality can result in the virus overwhelming health systems. Combinations of social distancing, and test, trace, and isolate strategies can reduce the number of new infections per infected individual below 1, thus driving declines in case numbers, but may be both challenging and costly. These interventions must also be maintained until development and (now likely) mass deployment of a vaccine (or therapeutics), since otherwise, many susceptible individuals are still at risk of infection. We use a simple analytical model to explore how low levels of infection, combined with vaccination, determine the trajectory to community immunity. Understanding the repercussions of the biological characteristics of the viral life cycle in this scenario is of considerable importance. We provide a simple description of this process by modelling the scenario where the effective reproduction number Reff is maintained at 1. Since the additional complexity imposed by the strength and duration of transmission-blocking immunity is not yet clear, we use our framework to probe the impact of these uncertainties. Through intuitive analytical relations, we explore how the necessary magnitude of vaccination rates and mitigation efforts depends crucially on the durations of natural and vaccinal immunity. We also show that our framework can encompass seasonality or preexisting immunity due to epidemic dynamics prior to strong mitigation measures. Taken together, our simple conceptual model illustrates the importance of individual and vaccinal immunity for community immunity, and that the quantification of individuals immunized against SARS-CoV-2 is paramount.
KW - Community immunity
KW - Natural and vaccinal immunity
KW - Sars-cov-2
UR - http://www.scopus.com/inward/record.url?scp=85100959689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100959689&partnerID=8YFLogxK
U2 - 10.1098/rsif.2020.0683
DO - 10.1098/rsif.2020.0683
M3 - Article
C2 - 33530857
AN - SCOPUS:85100959689
SN - 1742-5689
VL - 18
JO - Journal of the Royal Society Interface
JF - Journal of the Royal Society Interface
IS - 175
M1 - 20200683
ER -